Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15691438 | 0.79 | EGFR (0.58) | GRM4EGFRTRPA1CSNK2A1HPGD | |
| SCHEMBL6923487 | 0.74 | GRM4 (0.64) | GRM4EGFRTRPA1CSNK2A1 | |
| SCHEMBL6923707 | 0.74 | GRM4 (1.00) | GRM4TRPA1 | |
| SCHEMBL29496460 | 0.73 | GRM4 (1.00) | GRM4 | |
| SCHEMBL6923456 | 0.73 | GRM4 (0.72) | GRM4TRPA1 | |
| SCHEMBL2360210 | 0.73 | GRM4 (1.00) | GRM4 | |
| SCHEMBL6923576 | 0.72 | GRM4 (1.00) | GRM4TRPA1CSNK2A1 | |
| SCHEMBL6922868 | 0.70 | GRM4 (0.70) | GRM4 | |
| SCHEMBL4740555 | 0.70 | FADS1 (0.71) | GRM4EGFRTRPA1FADS1 | |
| SCHEMBL14201380 | 0.69 | EGFR (0.32) | GRM4EGFRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163015-B2 | Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011100607-A1 | PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | GRM4 1/4885EGFR 3588/4885TRPA1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.